Podcast
Questions and Answers
Which mutation is known as the 'gatekeeper' mutation that causes resistance to all currently available TKIs except ponatinib and asciminib?
What are the two phases defined for chronic myeloid leukemia (CML) as recommended by WHO?
Patients with which somatic variants may not benefit from TKIs or combination therapies and should be treated with allo-HSCT?
What is the median survival for CML-AP that evolves from CML-CP?
Signup and view all the answers
Which gene is NOT mentioned as one of the most frequently mutated in advanced-stage CML?
Signup and view all the answers
What is the primary genetic change associated with chronic myeloid leukemia (CML)?
Signup and view all the answers
What percentage of newly diagnosed leukemia cases in adults does CML account for?
Signup and view all the answers
What is a common initial manifestation of chronic phase (CML-CP)?
Signup and view all the answers
Which of the following statements about CML is false?
Signup and view all the answers
What role does the BCR::ABL1 oncoprotein play in CML?
Signup and view all the answers
Which phase of CML is characterized by the highest number of symptomatic patients?
Signup and view all the answers
Which of the following treatment approaches is used to manage resistance to TKIs in CML?
Signup and view all the answers
What causes the increased proliferation of CML cells?
Signup and view all the answers
What percentage of patients typically have the Ph chromosome?
Signup and view all the answers
Which is a common additional chromosomal abnormality seen in Ph-positive cells?
Signup and view all the answers
What is the typical translocation associated with Ph-positive CML?
Signup and view all the answers
Which variant of the BCR::ABL1 transcript is associated with a poor prognosis?
Signup and view all the answers
What is one characteristic that differentiates leukemoid reactions from CML?
Signup and view all the answers
What type of conditions can present with splenomegaly and neutrophilia?
Signup and view all the answers
Which cytogenetic abnormality is particularly associated with poor prognosis in CML?
Signup and view all the answers
What is the most consistent physical sign in patients with chronic myeloid leukemia (CML)?
Signup and view all the answers
What is a common characteristic of Polycythemia vera?
Signup and view all the answers
Which symptom is commonly associated with leukostatic effects in chronic myeloid leukemia?
Signup and view all the answers
What is the median platelet count in about 50% of patients with chronic myeloid leukemia?
Signup and view all the answers
What is a common laboratory finding in patients at the time of diagnosis of chronic myeloid leukemia?
Signup and view all the answers
In chronic myeloid leukemia, which of the following cell types typically shows a left shift in blood findings?
Signup and view all the answers
How is the absolute eosinophil count typically affected in chronic myeloid leukemia?
Signup and view all the answers
What classifies the presentation of CML in blast phase (CML-BP)?
Signup and view all the answers
What characterizes the peripheral blood smear in chronic-phase CML?
Signup and view all the answers
What is the median survival rate for patients typically unresponsive to TKI therapy?
Signup and view all the answers
What is the frontline therapy recommended for chronic myeloid leukemia (CML) chronic phase?
Signup and view all the answers
Which mutation is commonly associated with Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)?
Signup and view all the answers
What does MR4 in molecular response testing indicate?
Signup and view all the answers
Which TKI is considered a third-line therapy for CML?
Signup and view all the answers
What is a notable effect of second-generation TKIs on patient response?
Signup and view all the answers
Which follow-up method is recommended to monitor treatment response after starting therapy?
Signup and view all the answers
What is the primary mechanism of action of TKIs in the treatment of CML?
Signup and view all the answers
Study Notes
Chronic Myeloid Leukemia (CML)
- CML is a myeloproliferative neoplasm (MPN) caused by a genetic translocation between the ABL1 gene on chromosome 9 and the BCR gene on chromosome 22.
- This translocation leads to the expression of the BCR-ABL1 fusion protein, a constitutively active tyrosine kinase, causing aberrant cell growth and survival.
- CML prevalence is two cases/100,000, accounting for 15% of newly diagnosed leukemia cases in adults, with a slight male predominance.
- Tyrosine kinase inhibitors (TKIs) have dramatically reduced mortality rates to 2-3% per year.
CML Stages
- Chronic Phase (CP): Asymptomatic in 50% of cases, common signs include fatigue, weight loss, splenomegaly, and anemia due to excessive immature myeloid cells.
- Blast Phase (BP): Characterized by >20% blasts in the bone marrow, presents as acute leukemia, and has a much poorer prognosis compared to CP.
- Accelerated Phase (AP) is no longer considered a separate stage, categorized as high-risk CP.
Diagnosis and Differential Diagnosis
- Peripheral blood smear: Shows neutrophilia, myelocyte bulge, basophilia, and lack of dysplastic features. No increased blasts in the chronic phase.
- Cytogenetics: Ph chromosome (9;22) is detected in 90% of cases.
- Molecular testing: Detects the BCR-ABL1 fusion gene transcript, with different variants impacting prognosis.
- Differential Diagnosis: Includes leukemoid reactions, other MPNs, and MDS syndromes.
- Molecular Testing: Used to distinguish atypical CML from other conditions by detecting non-ABL1 mutations (e.g., SETBP1, SF3B1, CSF3R)
Treatment
- First-line therapy: TKIs (imatinib, dasatinib, bosutinib, nilotinib) are the standard of care for CML-CP.
- Second-line therapy: Second-generation TKIs (bosutinib, dasatinib, nilotinib, ponatinib) are used if resistance or intolerance develops to first-line TKIs.
- Third-line therapy: Ponatinib, asciminib, and allogeneic hematopoietic stem cell transplantation (Allo-HSCT) are options for patients with resistance to multiple TKIs.
- Allo-HSCT: Is not recommended as frontline therapy due to the efficacy of TKIs.
Monitoring Response to Therapy
- Bone marrow studies: Recommended at 3, 6, and 12 months after initiating therapy to assess response and disease progression.
- Molecular response (MR) testing: Evaluates the level of BCR-ABL1 transcripts in blood or bone marrow.
-
MR levels:
- MR1: BCR-ABL1 ≤ 10 cells per 100 cells
- MR2: BCR-ABL1 ≤ 1 cells per 100 cells
- MR3 (Major Molecular Response): BCR-ABL1 ≤ 1 cells per 1,000 cells
- MR4 (Deep Molecular Response): BCR-ABL1 ≤ 1 cells per 10,000 cells
- MR5 (Deep Molecular Response): BCR-ABL1 ≤ 1 cells per 100,000 cells
- Treatment-free remission (TFR): A potential treatment strategy for patients achieving deep molecular response after several years of TKI therapy.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Related Documents
Description
This quiz covers the essential aspects of Chronic Myeloid Leukemia (CML), including its genetic basis, prevalence, treatment options, and stages. Participants will learn about the BCR-ABL1 fusion protein and the implications of tyrosine kinase inhibitors on patient outcomes. Engage with the content to enhance your understanding of this myeloproliferative neoplasm.